Executive summary
US Patent 10,646,512 claims colon-cleansing compositions and kits built around an ascorbate component (50-60 g) plus PEG (10-50 g; PEG MW ~3000-4000 Da) with NaCl and KCl, optionally in two or more parts to make an admixture with 300–800 mL water (solution volume often 400–700 mL). Claim scope is centered on defined mass ranges, a specific ascorbate:PEG weight ratio (1.0–4.0:1), optional flavor/sweeteners, and a substantially bicarbonate-free limitation. The dependent kit claims add multi-sachet staging for preparing colon cleansing solutions. The landscape analysis and enforceable coverage depend on how broadly the invention is described in the specification (process and disclosure breadth), and on whether third-party products use PEG grades outside ~3000–4000 Da or use different osmotic salts/electrolyte systems.
H1: US Patent 10,646,512 scope and claims for ascorbate + PEG colon cleansing compositions and kits
What does US Patent 10,646,512 claim for colon cleansing compositions?
Core claim target: a composition for admixture with 300–800 mL water (or dry powder variant) that uses:
- Ascorbate component: 50–60 g (ascorbic acid, one or more ascorbate salts, or mixtures)
- PEG: 10–50 g
- Electrolytes: sodium chloride and potassium chloride
- Ratio constraint: ascorbate component : PEG weight ratio = 1.0 to 4.0 : 1
- Delivery range: optional presentation in two or more parts
- Optional additives: flavoring and sweeteners
- Exclusion: substantially free from bicarbonate (claim 10)
- PEG molecular weight: several claims specify average molecular weight 3000–4000 Da (claims 1, 2, 7, 11, 12, 13)
Independent claim 1 (structural elements)
Claim 1 is the structural backbone for composition coverage:
- Ascorbate component: 50–60 g
- PEG: 10–50 g
- NaCl + KCl
- Asc:PEG ratio: 1.0–4.0:1 by weight
- Admixture water: 300–800 mL
Independent claim 7 (ratio-by-parts format)
Claim 7 expresses the same concept using “parts”:
- Ascorbate anion 1.0–4.0 parts
- PEG 1.0 part
- NaCl 0.05–0.3 parts
- KCl 0.02–0.08 parts
This “parts” format typically maps to product formulations scaled to the final solution or intended batch, giving a second entry point for infringement arguments where absolute weights differ but ratios fall within the bands.
How broad are the composition claims and where are the key claim boundaries?
The claims have a narrow “formulation envelope” and a clear set of “design-around” levers.
Key boundaries (high leverage)
-
Ascorbate mass band (50–60 g)
Several claims require 50–60 g directly (claims 1, 2, 12, 13). Products outside that band likely fall outside those specific claims.
-
PEG quantity (10–50 g) and PEG grade (MW 3000–4000 Da)
- Claims 1/7/11/12/13 set PEG mass 10–50 g and often require PEG MW 3000–4000 Da.
- Claim 5 recites “comprising 40 g PEG,” implying embodiments at a specific PEG mass.
-
Electrolyte pair (NaCl + KCl)
Claim 1 requires both sodium chloride and potassium chloride. If a product uses different counterions or only one of the two, it can evade.
-
Asc:PEG ratio (1.0–4.0:1)
This is a primary structural limitation across the claim set.
-
Water admixture volume (300–800 mL)
The composition is defined for admixture in that range. Kits and directions outside that volume range can affect claim reach.
-
Bicarbonate exclusion (substantially free)
Claim 10 creates an explicit formulation limitation. A product with intentional bicarbonate or a formulation that is not “substantially free” is outside that dependent claim.
Ratio-specific electrolyte sub-bands (claim 8 and claim 11)
Claim 8 refines the electrolyte subranges:
- NaCl: 0.06–0.2 parts
- KCl: 0.03–0.07 parts
within the overall parts structure of claim 7.
Claim 3/4 specify absolute masses:
- NaCl: 1.5–3.5 g (claim 3)
- KCl: 1.0–2.5 g (claim 4)
These absolute dependent limits can provide enforcement leverage against “typical” packaging that matches the recited gram amounts.
Which PEG molecular weights are required, and how does that affect design-arounds?
Several claims tie PEG to a specific molecular weight window:
- PEG MW 3000–4000 Da in claims 2, 7, 11, 12, 13, and in multiple kit-related formulations (where the second composition is as in claim 1)
Kit staging claims introduce broader PEG coverage for a separate component
Claim 15/16 expands the PEG MW window for a different kit component:
- Claim 15A: first component includes PEG MW 2500–4500 Da and includes additional salts such as alkali/alkaline earth sulfates.
- Claim 15B: second component is the ascorbate+NaCl+KCl+PEG system, again within the ascorbate/PEG bands tied to claim 1.
Practical effect: a product can potentially design around by using PEG outside the 3000–4000 window in the ascorbate-containing step, while still using PEG within 2500–4500 in other steps. That lets manufacturers preserve overall osmotic performance while aiming to avoid the “as-cited” MW limitation.
What formulations are explicitly covered: solution vs dry powder and bicarbonate-free?
Solution admixture (volume defined)
- Claim 1: admixture with 300–800 mL water
- Claim 6: volume 400–700 mL (narrower)
Dry powder variant
- Claim 9: claim 7 composition is a dry powder.
This helps capture product formats where the sachet contents are dosed as a powder and added to water at the point of administration.
Substantially bicarbonate-free
- Claim 10: composition is substantially free from bicarbonate.
This is an explicit negative limitation that can be used in enforcement where competing products use bicarbonate salts as buffering or CO2-related systems.
How do claims 14–16 cover kits and multi-sachet colon cleansing workflows?
The kit claims add a second infringement axis: not just the formulation, but the packaging and staged preparation for a colon cleansing solution.
Claim 14: three-sachet kit staging
- First sachet: first composition for a first colon cleansing solution
- Second + third sachets: together provide the claim 1 composition for a second colon cleansing solution
This is important because claim 1 itself allows “optionally presented in two or more parts.” Claim 14 turns that option into a required kit structure with distinct sachets.
Claim 15: first component includes sulfates and PEG; second component is the ascorbate+PEG+NaCl+KCl stage
Claim 15 structure:
- Component 1: PEG 2500–4500 Da plus 1.5–15 g of alkali metal/alkaline earth metal sulfates (or mixture). Optional electrolytes, flavoring, sweeteners.
- Component 2: “two or more parts” and provides the claim 1 composition for a colon cleansing solution of volume 300–800 mL
- Second component includes:
- ascorbate component 50–60 g
- PEG 10–50 g
- NaCl + KCl
- asc:PEG ratio 1.0–4.0:1
Claim 16: further split within the second component
Claim 16 specifies:
- Third sachet contains ascorbic acid
- Second sachet (B1) contains PEG MW 2500–4500 and NaCl/KCl and/or ascorbic acid salts
- Together, B1 + B2 provide 50–60 g ascorbate component
Practical coverage note: staged kits let manufacturers separate components for stability, taste masking, or dosing accuracy. Claim 16’s structure can be used to argue infringement even if the ascorbate is physically split across two sachets, so long as the total packaging and ratios match the claim envelope.
What specific claim elements map to potential infringement evidence?
For litigation or freedom-to-operate, the claim set suggests a focused evidence checklist:
-
Quantitative label content per dose
- Ascorbate: verify 50–60 g
- PEG mass: verify 10–50 g (or exact disclosed embodiment like 40 g)
- NaCl and KCl: verify gram bands (claims 3/4) or ratio bands (claims 7/8)
-
PEG grade
- Confirm whether PEG is in 3000–4000 Da for the ascorbate-containing component.
- For kit component 1, confirm PEG within 2500–4500 Da.
-
Electrolyte system
- Confirm the presence of both NaCl and KCl.
- Check absence/presence of bicarbonate for claim 10.
-
Preparation instructions
- Water volume targeted: 300–800 mL or 400–700 mL.
-
Packaging format
- Confirm the number and content of sachets/components for kit claims 14–16.
How strong is the patent estate for this invention based on claim drafting features?
From the claim text alone, the drafting has two strengths:
- Clean formulation boundaries: explicit mass ranges, ratio constraints, MW windows, and electrolyte pairing.
- Multiple claim entry points: independent claims in both absolute grams (claim 1) and parts/ratios (claim 7), plus kit-dependent claims.
Main weakness for broad enforcement: the scope is tied tightly to the formulation envelope. A product that changes:
- ascorbate identity (still ascorbate salts likely still captured),
- removes potassium chloride,
- shifts PEG grade outside 3000–4000 Da for the ascorbate-containing step,
- moves admixture volume outside 300–800 mL,
- uses bicarbonate buffers beyond “substantially free,”
can create design-around leverage.
What generic or competitor entry risks exist under these claim limitations?
High risk scenario (closest copy)
A competitor that markets a split sachet colon cleanser where the ascorbate-containing step uses:
- 50–60 g ascorbate per dose,
- 10–50 g PEG (MW ~3000–4000),
- both NaCl and KCl,
- asc:PEG ratio 1.0–4.0:1,
- admixture with 300–800 mL,
- no significant bicarbonate,
faces elevated exposure under claims 1/2/7/11/12/13 and dependent constraints.
Medium risk scenario (partial matching with kit structure)
If the competitor matches the kit staging but shifts the ascorbate-containing component PEG MW or electrolyte grams slightly, the risk moves from “straight claim 1” coverage to claim 7 ratio coverage or dependent subranges (claims 3/4/8).
Lower risk scenario (targeted design-around)
Design-arounds that likely avoid the most direct claim read:
- use PEG outside 3000–4000 Da for the ascorbate-containing step,
- replace KCl with different potassium salts or eliminate potassium,
- introduce bicarbonate such that it is not “substantially free,”
- modify the dosage so the ascorbate band is outside 50–60 g.
Kit claims also require the specific staged component design, so a competitor with different sachet content partitioning may reduce the kit-claim fit even if the final mixture ends up similar.
How do the claim 15–16 kit elements compare with typical US OTC/Prescription bowel prep products?
These claims are consistent with a two-step or multi-part regimen:
- one component with PEG + sulfate salts,
- another component with ascorbate + NaCl/KCl + PEG for the second solution volume.
The key differentiation for this patent is the ascorbate + PEG + NaCl/KCl chemistry in the second solution preparation and the staging into multiple sachets with specific ranges.
A competitor that uses classic osmotic systems (for example, sodium sulfate/magnesium sulfate systems or PEG-electrolyte formulations without ascorbate substitution) may not align with the ascorbate-based claim elements.
What questions matter for patent validity challenges and claim construction?
This section is grounded in typical US claim construction issues raised by this claim style:
- “Substantially free from any bicarbonate” creates a construction question tied to the specification and analytical thresholds. The limitation is qualitative, but it can still be enforced using product testing.
- PEG “average molecular weight” requires definition of how MW is measured (manufacturer specification or analytical method). The claim already ties to a narrow window for the ascorbate-containing component, so construction affects infringement.
- Parts-based ratios (claim 7/8) can create disputes over what constitutes a “part” in a scaled formulation. Claim interpretation may track the formulation described in the specification and examples.
- Kit claims often face construction around whether “together provide” means co-administration in the same regimen versus physical mixing at the consumer level.
Key takeaways
- US 10,646,512 is a formulation and kit patent for colon cleansing that centers on ascorbate (50–60 g) combined with PEG (10–50 g) and NaCl + KCl, constrained by ascorbate:PEG ratio (1.0–4.0:1) and often PEG MW 3000–4000 Da.
- Independent coverage is split across:
- Absolute formulation limits (claim 1, claims 2/3/4/5/6/12/13) and
- Ratio “parts” formulation limits (claim 7 and claim 8).
- A major enforceability lever is the kit staging in claims 14–16, which ties component partitioning to the ascorbate-containing preparation step.
- The most direct design-arounds are changes to (i) PEG MW in the ascorbate step, (ii) potassium salt inclusion, (iii) bicarbonate presence, and (iv) dosing mass/ratio and water volume.
FAQs
- What happens if a product uses ascorbic acid but outside the 50–60 g per dose range in US 10,646,512 claim 1?
- Does using PEG with average molecular weight just above 4000 Da avoid claim 1 and claim 2?
- Can a competitor infringe the ratio-based claims (7/8) even if it changes absolute gram amounts?
- How does “substantially free from any bicarbonate” affect testing and litigation strategy?
- What kit assembly choices most reduce risk under claims 14–16?
References (APA)
No patent bibliographic sources were provided with the prompt beyond the US patent number and the claim text, so no external sources can be cited without introducing uncited facts.
